Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have earned an average rating of "Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rati...